Last Updated Oct 8, 2009 3:52 PM EDT
This May 14, 2001, email from Debbie Holdsworth to Seroquel Product Managers states:
- Seroquel has a neutral effect on weight during long-term treatment.
- Seroquel is not associated with diabetes nor its exacerbation.
Aug. 13, 1997, memo from Lisa Arvanitis to her colleagues: 1. Is there a competitive advantage for SEROQUEL re-weight gain which we can articulate in posters/talks/vis aids? We know we have weight gain but is it limited to the short term --? -- I was really struck by how consistent the data was.By 2001, AZ had constructed this brochure, titled, "Distinct advantages of a favorable weight profile." It is confusing to say the least. It starts by saying:
- Minimal weight gain may reduce the likelihood that treatment with Seroquel will lead to diabetes and other morbidities associated with weight gain.Read that sentence carefully. It's meaningless. The brochure then concludes:
As with other antipsychotic agencts, SEROQUEL has been associated with weight gain. However, in a placebo-controlled clinical trial, weight gain ranged from 0.9kg to 2.6kg.(Translation for Americans: 0.9kg is about 2 pounds, and 2.6kg is nearly 6 pounds.)
If you look at the population as a whole, some are below weight, some are average weight and some are above weight, so that taken together, the effect of Seroquel is weight neutral.Put another way, Patterson seems to believe that if you gain 5 pounds in weight but I lose 15 pounds, then we have -- "taken together" -- both lost 10 pounds.
- AZ Call Notes Expose Secret Life of Seroquel Reps ... And It's Mostly Scandal-Free
- AstraZeneca Q2: $593M Seroquel Legal Bill Taps Out Insurance; Income Charges Expected
- Bad News for AstraZeneca on Seroquel Resumes After Brief Respite
- Seroquel Lawyers: AstraZeneca Has Lulled Itself Into a False Sense of Security
- AstraZeneca Seems to Be Winning the War Against Seroquel
- AstraZeneca to Seroquel Patient: You Have Diabetes Because You're Black
- Seroquel Trial: More Emails From MacFadden, AZ's Sex-for-Studies Exec, Emerge